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  P
ostnatal depression (PND) 
occurs in 10 to 15 percent of 
mothers [1] and is therefore 
the commonest complication of 
childbearing. The morbidity of PND 
for the mother and its potentially 
negative associations with neonatal and 
child development and on other family 
members are well established [2–4]. In 
theory, the antenatal period and early 
puerperium are opportune times to 
implement interventions to prevent 
PND because mothers are in frequent 
contact with health professionals. It 
is also increasingly recognised that 
some women who are diagnosed with 
depression postnatally have been 
depressed during the antenatal period 
[5,6], so it is important to detect 
and treat symptoms of depression 
antenatally to reduce the incidence 
of PND. We have therefore recently 
carried out a Cochrane review of 
antidepressant prevention of postnatal 
depression (see Text S1).
  The  Review
    We sought to discover whether 
antidepressant drugs are effective in 
the prevention of postnatal depression, 
to compare the effectiveness of 
different antidepressant drugs, with or 
without any other form of prevention 
for postnatal depression, i.e. hormonal 
treatment and psychological or social 
support, and to assess any adverse 
effects of antidepressant drugs in either 
the mother or the foetus/infant.
    Criteria for inclusion were 
all published and unpublished 
randomised controlled trials of 
antidepressants to prevent postnatal 
depression in women who were 
pregnant or had given birth in the 
previous six weeks and who were not 
taking any antidepressant medication 
at the start of the trial. Women who 
had already been diagnosed with 
antenatal depression were excluded. 
Literature from 1945 to 2004 was 
methodically screened; this included 
a comprehensive literature search 
of electronic databases and was 
supplemented by hand searching and 
personal communication. 
    Two small studies fulﬁ  lled inclusion 
criteria for this review. No unpublished 
studies were identiﬁ  ed. Both examined 
the effect of antidepressants initiated 
within 24 hours of delivery in women 
with a history of at least one episode 
of postnatal depression. The ﬁ  rst 
study [7], with 51 participants, found 
that nortriptyline was no more 
effective than placebo in preventing 
a recurrence of postpartum major 
depressive disorder. The second trial 
[8] reported that sertraline was more 
effective than placebo in preventing 
a recurrence of postpartum major 
depression. Of fourteen patients who 
took sertraline, only one suffered a 
recurrence. In contrast, out of eight 
patients assigned to placebo, four 
(50%) suffered recurrences (  p   = 0.04), 
and the time before recurrence was 
longer in the sertraline-treated women 
compared with placebo-treated women 
(  p   = 0.012). Adverse effects found 
were headaches in two patients and 
hypomania in one patient, leading 
to withdrawal of all three patients. 
Dizziness and drowsiness were also 
reported signiﬁ  cantly more often in the 
sertraline group.
    A meta-analysis was not carried 
out because the two trials involved 
pharmacologically very different 
antidepressants.
    Implications of the Review
    Both studies had serious 
methodological limitations, which 
means that no clear conclusions can 
be drawn about the effectiveness of 
antidepressants in preventing postnatal 
depression. The nortriptyline trial may 
have been statistically underpowered, 
and less than half the women eligible 
for the trial took part. The second 
small trial found some evidence that 
sertraline was effective in preventing 
postnatal depression, but only 25 
women were recruited in total and the 
data were not subjected to an intention-
to-treat analysis. This randomised 
controlled trial only included 
white married women of middle to 
high socioeconomic status and the 
nortriptyline trial did not give details 
of sociodemographic characteristics; 
the women were therefore not 
representative of women at risk of 
PND. The studies also excluded women 
taking antidepressants in the ﬁ  rst 
trimester. Both trials included breast-
feeding women but did not give details 
of any adverse effects on the infants 
and did not follow up infants exposed 
to the antidepressants to examine 
neurodevelopmental outcomes in the 
long term. 
    The group of women at highest risk 
of PND because of a recent history of a 
major depressive episode [5] may take 
antidepressants at conception as part 
of relapse prevention. Continuation 
of antidepressants through pregnancy 
in such women may prevent postnatal 
depression, but this was not tested in 
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these studies. Antidepressants may also 
be more likely to prevent postnatal 
depression if medication is used which 
successfully treated previous episodes 
of depression. In addition, the trials did 
not compare antidepressant therapy 
with any other form of treatment, and 
both trials had very short periods of 
follow-up time with no assessment of 
the impact on the infant. The paucity 
of trials in this area and the small size 
of the trials published may reﬂ  ect a 
reluctance to recruit women in the 
postpartum period into antidepressant 
trials, as there is evidence from studies 
of treatment of PND that women are 
often unwilling to take antidepressants 
[9,10]. There is particular concern 
regarding prescribing antidepressants 
when women are breast-feeding, 
as there is limited evidence on the 
extent to which infants are exposed 
to antidepressants through breast 
milk and the long-term effect this may 
have on the infant [11]. The evidence 
therefore does not allow us to make 
any recommendations about the 
role of antidepressants in preventing 
postpartum depression.
    Future research should reﬁ  ne 
the identiﬁ  cation of high-risk 
women, compare the effectiveness 
of antidepressants and psychosocial 
treatments for women with depression 
in the postnatal period, and carry out 
long-term follow-up of women and 
their children, including monitoring 
of adverse effects for the mother and 
infant.  
    At present, although there have 
been many trials of psychological 
and psychosocial interventions to 
prevent PND, there is little evidence 
of effectiveness for these interventions 
[12,13]. This may partly reﬂ  ect the 
problem of identifying women at high 
risk of PND, and several studies have 
therefore targeted all women, either 
during pregnancy or in the early 
postnatal period. However, a systematic 
review of preventative interventions 
for PND found that identifying women 
“at risk” assisted in the prevention 
of postnatal depression. In addition, 
postnatal interventions were found 
to be more effective than antenatal 
interventions, and individually based 
interventions were more effective than 
group interventions [12]. Guidelines 
based on a review of the available 
evidence have concluded that in 
high-risk women it may be effective to 
provide postnatal visits, interpersonal 
therapy, and/or educational 
programmes on preparation for 
parenthood [13]. As the prescription 
of antidepressants is difﬁ  cult in the 
postnatal period, for the reasons 
detailed above, the current evidence 
base therefore supports offering 
women at risk of PND intensive 
professionally based postpartum 
support for prevention of PND.  
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